The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, after posting that it had hit all primary and secondary endpoints for the treatment of ankylosing spondylitis.
Lilly’s Taltz was the second IL-17 treatment to be approved in psoriasis, in 2016, and then later last year in psoriatic arthritis. However, Novartis’ drug has been approved in plaque psoriasis since the beginning of 2015 – giving it plenty of space to build up its lead in the area.
